Advanced Search
Contact | Corporate | Help

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Sponsors:
  • Forest Laboratories
  • Almirall, S.A.
Phases:
  • Phase III
IndicationsAcronym:
LAC
  • Chronic Obstructive Pulmonary Disease
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Aclidinium Bromide/Formoterol Fumarate
  • Drug: Aclidinium Bromide/Formoterol Fumarate
  • Drug: Aclidinium Bromide
  • Drug: Formoterol Fumarate
  • Drug: placebo
Enrollment:
1550

Additional information about NCT01437397.


SourceSolution © 2008-2012